Chamber and committees

Questions and answers

Parliamentary questions can be asked by any MSP to the Scottish Government or the Scottish Parliamentary Corporate Body. The questions provide a means for MSPs to get factual and statistical information.

Written questions must be answered within 10 working days (20 working days during recess)
Other questions such as Topical, Portfolio, General and First Minister's Question Times are taken in the Chamber

Urgent Questions aren't included in the Question and Answers search. There is a SPICe fact sheet listing Urgent and emergency questions.

Find out more about parliamentary questions

Filter your results Hide all filters

Displaying 2302 questions Show Answers

Order by |

Question reference: S3W-39917

Asked by: Rhoda Grant, MSP for Highlands and Islands, Scottish Labour
Date lodged: Thursday, 24 February 2011
Current Status: Answered by Nicola Sturgeon on 10 March 2011

Question reference: S3W-39888

Asked by: Rhoda Grant, MSP for Highlands and Islands, Scottish Labour
Date lodged: Thursday, 24 February 2011
Current Status: Answered by Shona Robison on 10 March 2011

To ask the Scottish Executive what the cost has been for drugs prescribed for diabetes treatment in NHS Orkney in each of the last four years for which information is available.

The following table shows the gross ingredient cost for drugs defined by the British National Formulary as involved in the treatment of diabetes dispensed in the community-by-community pharmacists and dispensing doctors for the financial years ended 31 March 2007 to 2010 for NHS Orkney. The data exclude the direct supply of medicines to patients from hospitals and hospital-based clinics.

Financial Year	Gross Ingredient Cost (£)
2006-07	140,736
2007-08	145,558
2008-09	150,501
2009-10	156,756

Notes: The data are based on British National Formulary subsections 6.1.1 and 6.1.2.

Gross ingredient cost is the cost of an item before any discounts are applied. It excludes adjustments and broken bulk fees.

The information in the table has been provided by NHS National Services Scotland. Further information on prescribing can be found at www.isdscotland.org/prescribing.

Question reference: S3W-39918

Asked by: Rhoda Grant, MSP for Highlands and Islands, Scottish Labour
Date lodged: Thursday, 24 February 2011
Current Status: Answered by Nicola Sturgeon on 10 March 2011

Question reference: S3W-39916

Asked by: Rhoda Grant, MSP for Highlands and Islands, Scottish Labour
Date lodged: Thursday, 24 February 2011
Current Status: Answered by Nicola Sturgeon on 10 March 2011

Question reference: S3W-39920

Asked by: Rhoda Grant, MSP for Highlands and Islands, Scottish Labour
Date lodged: Thursday, 24 February 2011
Current Status: Answered by Nicola Sturgeon on 10 March 2011

Question reference: S3W-39887

Asked by: Rhoda Grant, MSP for Highlands and Islands, Scottish Labour
Date lodged: Thursday, 24 February 2011
Current Status: Answered by Shona Robison on 10 March 2011

To ask the Scottish Executive what the cost has been for drugs prescribed for diabetes treatment in NHS Highland in each of the last four years for which information is available.

The following table shows the gross ingredient cost for drugs defined by the British National Formulary as involved in the treatment of diabetes dispensed in the community by community pharmacists and dispensing doctors for the financial years ended 31 March 2007 to 2010 for NHS Highland. The data exclude the direct supply of medicines to patients from hospitals and hospital-based clinics.

Financial Year	Gross Ingredient Cost (£)
2006-07	2,735,807
2007-08	2,898,461
2008-09	2,868,970
2009-10	3,144,538

Notes: The data are based on British National Formulary subsections 6.1.1 and 6.1.2.

Gross ingredient cost is the cost of an item before any discounts are applied. It excludes adjustments and broken bulk fees.

The information in the table has been provided by NHS National Services Scotland. Further information on prescribing can be found at www.isdscotland.org/prescribing.

Question reference: S3W-39890

Asked by: Rhoda Grant, MSP for Highlands and Islands, Scottish Labour
Date lodged: Thursday, 24 February 2011
Current Status: Answered by Shona Robison on 10 March 2011

To ask the Scottish Executive what the cost has been for drugs prescribed for diabetes treatment in NHS Western Isles in each of the last four years for which information is available.

The following table shows the gross ingredient cost for drugs defined by the British National Formulary as involved in the treatment of diabetes dispensed in the community by community pharmacists and dispensing doctors for the financial years ended 31 March 2007 to 2010 for NHS Western Isles. The data exclude the direct supply of medicines to patients from hospitals and hospital-based clinics.

Financial Year	Gross Ingredient Cost (£)
2006-07	253,548
2007-08	267,163
2008-09	269,452
2009-10	296,976

Notes:

The data are based on British National Formulary subsections 6.1.1 and 6.1.2.

Gross ingredient cost is the cost of an item before any discounts are applied. It excludes adjustments and broken bulk fees.

The information in the table has been provided by NHS National Services Scotland. Further information on prescribing can be found at www.isdscotland.org/prescribing.

Question reference: S3W-39919

Asked by: Rhoda Grant, MSP for Highlands and Islands, Scottish Labour
Date lodged: Thursday, 24 February 2011
Current Status: Answered by Nicola Sturgeon on 10 March 2011

The information requested is not centrally held for 2007.

Information for 2008-09 and 2009-10 is as follows:

Year	Grampian WTE	Highland WTE	Orkney WTE	Shetland WTE	Western Isles WTE
2008-09	74.5	62.7	5.9	22.0	11.0
2009-10	36.0	62.9	6.1	35.0	11.0

Year

Grampian

WTE

Highland

WTE

Orkney

WTE

Shetland

WTE

Western Isles

WTE

2008-09

74.5

62.7

5.9

22.0

11.0

2009-10

36.0

62.9

6.1

35.0

11.0

Source: Annual Accounts.

Note: The annual mean number of employees is calculated as the total whole-time equivalent (WTE) number of employees under contract of service in each week in the financial year, divided by the number of weeks in the financial year.

Information for 2010-11 will be available when NHS boards produce their annual accounts for 2010-11 at the end of June.

Question reference: S3W-39898

Asked by: Rhoda Grant, MSP for Highlands and Islands, Scottish Labour
Date lodged: Thursday, 24 February 2011
Current Status: Answered by Shona Robison on 10 March 2011

To ask the Scottish Executive how many (a) independent and (b) salaried dentists in the Highlands and Islands area received the £9,000 remote areas allowance in each of the last three years for which information is available.

The number of (a) independent and (b) salaried dentists in the Highland and Islands area who received the £9,000 remote areas allowance in each of the last three years for which information is available is shown in the following table:

Dentists	2008-09	2009-10	2010-11 (to date)
(a) independent	19	24	27
(b) salaried	30	34	41

Dentists

2008-09

2009-10

2010-11

(to date)

(a) independent

(b) salaried

The figures in the table do not include (a) independent and (b) salaried dentists who have received, in the last three years, the remote areas allowance payable at amounts of less than the full £9,000.

Question reference: S3W-39883

Asked by: Rhoda Grant, MSP for Highlands and Islands, Scottish Labour
Date lodged: Thursday, 24 February 2011
Current Status: Answered by Shona Robison on 9 March 2011

To ask the Scottish Executive what the percentage rate in the uptake of women aged 20 to 24 attending cervical screening has been in NHS Orkney in each of the last four years for which information is available and how these figures compare with the overall average of all age groups attending.

The percentage uptake¹ of females who had a record of a previous screening test taken within the last 3.5 years, by five year age group is in the following table.

NHS Orkney, 1 January 2006 to 31 March 2010

Age Group	2006-07	2007-08	2008-09	2009-10
Age Group	% Uptake	% Uptake	% Uptake	% Uptake
20-24	60.5	53.8	59.9	61.5
25-29	80.6	69.3	72.0	74.3
30-34	84.8	72.0	77.5	76.2
35-39	83.5	76.1	82.8	82.4
40-44	86.0	79.1	82.6	83.3
45-49	90.0	80.9	83.7	84.2
50-54	87.3	82.0	82.5	81.8
55-59	83.8	81.0	81.4	81.9
60-64	63.7	74.6	72.7	60.7
20-60	83.4	75.7	79.0	79.3
Total (All Ages)	46.9	75.3	78.1	77.3

The percentage uptake¹ of females who had a record of a previous screening test taken within the last 5.5 years, by five year age group is in the following table.

Age Group	2006-07	2007-08	2008-09	2009-10
Age Group	% Uptake	% Uptake	% Uptake	% Uptake
20-24	60.8	57.5	61.5	63.0
25-29	86.0	79.5	80.1	77.5
30-34	89.9	81.3	82.6	82.0
35-39	89.2	84.3	86.8	86.3
40-44	90.7	85.8	86.5	87.2
45-49	93.3	87.0	88.7	88.4
50-54	92.6	88.1	86.7	86.6
55-59	89.8	86.6	86.4	86.2
60-64	80.6	83.3	84.3	81.7
20-60	88.0	82.6	83.6	83.4
Total (All Ages)	51.1	82.4	83.3	82.9

Source: ISD(D)4 Legacy application for 2006-07 data.

Source: ISD(D)4 Scottish Cervical Call-Recall System (SCCRS) for 2007-08 data onwards.

Ref: IR2011-00573.

Notes:

1. Based on adjusted Community Health Index (CHI) population denominator (excluding medically ineligible women) for 2006-07. Based on SCCRS population denominator (excluding medically ineligible women) for years 2007-08 to 2009-10.

Cervical Screening year runs from 1 April to 31 March.